Stock ADXN ADDEX THERAPEUTICS LTD
Add to a list
To use this feature you must be a member
Log inSign up

News Addex Therapeutics Ltd

Equities

ADXN

CH0029850754

Market Closed - Swiss Exchange
Other stock markets
 11:30:38 2024-04-18 am EDT 		5-day change 1st Jan Change
0.1595 CHF -14.71% Intraday chart for Addex Therapeutics Ltd -18.21% +246.74%
Apr. 18 Transcript : Addex Therapeutics Ltd, 2023 Earnings Call, Apr 18, 2024
Apr. 18 Addex Therapeutics Ltd Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Transcript : Addex Therapeutics Ltd, 2023 Earnings Call, Apr 18, 2024
Addex Therapeutics Ltd Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Addex Therapeutics Logs Decline in FY23 Net Loss; Revenue Rises
MT
Addex Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update
GL
Addex Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update
DJ
Addex Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update
AQ
Addex Therapeutics to Release Full-Year 2023 Financial Results and Host Conference Call on April 18, 2024
GL
ADRs End Higher; Biophytis Climbs 30%
DJ
Wall Street Set to Open Slightly Higher as Investors Await Wednesday's Inflation Data
MT
Top Premarket Gainers
MT
ADRs Advance, Eco Wave Power Global AB Climbs 213.4%
DJ
Powell Speech Eyed, Intel Weighs on Sentiment as US Equity Futures Waver Premarket
MT
Top Premarket Gainers
MT
Addex Therapeutics Announces the Launch of Neurosterix, Company Focused on Developing Allosteric Modulators for the Treatment of Underserved Neurological Disorders
CI
Addex and Perceptive Launch Neurosterix with $63 Million to Accelerate Development of Allosteric Modulator Therapeutics for Neurological Disorders
DJ
Addex and Perceptive Launch Neurosterix with $63 Million to Accelerate Development of Allosteric Modulator Therapeutics for Neurological Disorders
GL
Addex to Present at the Bio-Europe Spring 2024 Conference
GL
ADRs Close Lower, Lixiang Education Holding Co. Ltd. Declines 19.6%
DJ
Addex Therapeutics Plans Sale of American Depositary Shares
MT
Addex Enters into At-The-Market ADS Offering Agreement with H.C. Wainwright & Co. LLC.
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ADXN Stock
  4. News Addex Therapeutics Ltd